Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus

Morel, Chantal M.Uppsala universitet,Företagsekonomiska institutionen,Univ Geneva Hosp, Rue Gabrielle Perret Gentil 4, CH-1205 Geneva, Switzerland.;Fac Med, Rue Gabrielle Perret Gentil 4, CH-1205 Geneva, Switzerland.;Global Studies Inst, Rue Vieux Grenadiers 10, CH-1205 Geneva, Switzerland. (author)

Industry incentives and antibiotic resistance : an introduction to the antibiotic susceptibility bonus

The scarcity of novel antibiotic compounds in a time of increasing resistance rates has begun to ring alarm bells at the highest echelons of government. Large new financial incentives to accelerate antibiotic research and development, such as market entry rewards (MERs), are being considered. However, there is little focus on how to sustain the efficacy of new, promising antibiotics reaching the market. Currently, inappropriate use of antibiotics is commonplace, which has accelerated resistance development. In an attempt to halt this trend, antibiotic stewardship policies are being implemented in many resource-rich settings. Unfortunately, this has not yet had an impact on the amount of antibiotics being prescribed globally. One important hurdle is misalignment of incentives. While governments and health services are incentivized to promote prudent use of this common good, pharmaceutical companies are incentivized to increase volume of sales to maximize profits. This problem must be addressed or else the major efforts going into developing new antibiotics will be in vain. In this paper we outline an approach to realign the incentives of pharmaceutical companies with wider antibiotic conservation efforts by making a staged bonus a component of an MER for antibiotic developers when resistance to their drug remains low over time. This bonus could address the lack of stewardship focus in any innovation-geared incentive.

Lindahl, Olof,1982-Uppsala universitet,Företagsekonomiska institutionen(Swepub:uu)ololi123 (author)
Harbarth, StephanUniv Geneva Hosp, Infect Control Programme, Rue Gabrielle Perret Gentil, CH-41205 Geneva, Switzerland.;Univ Geneva Hosp, Div Infect Dis, Rue Gabrielle Perret Gentil, CH-41205 Geneva, Switzerland.;Fac Med, Rue Gabrielle Perret Gentil, CH-41205 Geneva, Switzerland.;Univ Geneva Hosp, WHO Collaborating Ctr Patient Safety, Rue Gabrielle Perret Gentil, CH-41205 Geneva, Switzerland. (author)
de Kraker, Marlieke E. A.Univ Geneva Hosp, Rue Gabrielle Perret Gentil 4, CH-1205 Geneva, Switzerland.;Fac Med, Rue Gabrielle Perret Gentil 4, CH-1205 Geneva, Switzerland. (author)
Edwards, SuzanneBerlin Univ Technol, Dept Hlth Care Management, Berlin, Germany. (author)
Hollis, AidanUniv Calgary, Dept Econ, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada. (author)
Uppsala universitetFöretagsekonomiska institutionen (creator_code:org_t)

In:Journal of antibiotics (Tokyo. 1968): NATURE PUBLISHING GROUP73:7, s. 421-4280021-88201881-1469

By the author/editor: Morel, Chantal M ...; Lindahl, Olof, 1 ...; Harbarth, Stepha ...; de Kraker, Marli ...; Edwards, Suzanne; Hollis, Aidan

About the subject

SOCIAL SCIENCES: SOCIAL SCIENCES; and Economics and Bu ...; and Business Adminis ...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.